Risperidone sustained-release - Indivior

Drug Profile

Risperidone sustained-release - Indivior

Alternative Names: Long-acting Risperidone - Indivior; RBP 7000

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Indivior
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Schizophrenia

Most Recent Events

  • 02 Oct 2017 Adverse events data from a phase III trials in Schizophrenia released by Indivior
  • 02 Oct 2017 DURECT Corporation signs a patent purchase agreement with Indivior for risperidone sustained-release for Schizophrenia
  • 02 Oct 2017 Indivior has patent protection for risperidone sustained-release in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top